focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 38.75
Change: -0.575 (-1.47%)
Spread: 0.25 (0.649%)
Open: 39.05
High: 39.20
Low: 39.00
Prev. Close: 39.20
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing and Distribution Agreements with TTK

13 Jun 2016 07:00

RNS Number : 9244A
Futura Medical PLC
13 June 2016
 

For immediate release

13 June 2016

 

 

Futura Medical plc

("Futura" or the "Company")

 

Signs Manufacturing and Distribution Agreements with TTK

 

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has signed manufacturing and distribution agreements with TTK Protective Devices Limited ("TTK"), a pioneer in the condom business and part of the substantial Indian conglomerate TTK Group.

 

Under the terms of the manufacturing agreement, TTK will manufacture CSD500, Futura's novel erectogenic condom for supply worldwide. A regulatory filing has already been made with EU regulatory authorities to grant TTK the relevant authorisation to manufacture the product.

 

TTK will be one of two manufacturers of CSD500 as part of the Company's strategy to guarantee international supply. A European manufacturer already holds regulatory authorisation to manufacture the version of CSD500 currently marketed in the Netherlands and is awaiting regulatory authorisation for the extended shelf-life version of the product.

 

Futura has also signed an exclusive licensing agreement with TTK for the marketing and distribution of CSD500 in India for the lifetime of the patents. Futura will receive an upfront payment and royalties on product sales over the duration of the agreement.

 

TTK already owns the fastest growing condom brand in India, SKORE, which since its launch three years ago has achieved in excess of a 10% market share. TTK is attracted by the unique characteristics of CSD500 to further drive the growth of the SKORE brand. Subject to regulatory approval, CSD500 is expected to be launched by TTK in Q1 2017.

 

James Barder, Futura Medical's Chief Executive, said: "I am delighted to sign these two agreements for worldwide manufacturing and for distribution in India of our novel erectogenic condom, CSD500. It has always been our manufacturing strategy to offer CSD500's licensees the guarantee of supply by having dual sourced manufacture in Europe and in Asia. TTK is an ideal manufacturing partner as it is a highly experienced condom maker that has supplied the world's largest condom brands.

 

"I am also delighted to sign an exclusive agreement with TTK for the marketing and distribution of CSD500 in India. TTK's SKORE brand is the fastest growing condom brand in India and we look forward to CSD500 becoming a further growth driver in the SKORE franchise."

 

Mr T T Raghunathan, TTK Protective Device's Managing Director, said: "We are very pleased to be working with Futura Medical both in manufacturing CSD500 for worldwide supply and in distributing the product in India. TTK has always stood for innovation and quality in the global condom market, in which we have a long track record in manufacturing high quality condoms. We also look forward to the success of combining India's fastest growing condom brand, SKORE, with the innovation that CSD500 brings to condom users."

 

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz YongCorporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGGURUQUPQGQU
Date   Source Headline
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares
10th Sep 20157:00 amRNSGrant of Options
9th Sep 20157:00 amRNSInterim Results
19th Aug 20153:15 pmRNSNotification of Major Interest in Shares
19th Aug 20157:00 amRNSNotice of Interim Results
16th Jul 20154:23 pmRNSNotification of Major Interest in Shares
14th Jul 20157:00 amRNSHeadline Results from Pain Relief Study
13th Jul 20157:00 amRNSNotice of Pain Relief Portfolio Study Results
25th Jun 20157:00 amRNSCommencement of MED2002 Clinical Trial
17th Jun 20155:45 pmRNSResult of AGM
17th Jun 20157:00 amRNSAGM Statement
3rd Jun 20155:20 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20157:00 amRNSPain Relief Portfolio: Study Update
11th May 20157:00 amRNSBlock Listing Update
11th May 20157:00 amRNSBlue Diamond® Retail Roll-out
24th Apr 20153:00 pmRNSNotice of AGM
31st Mar 20155:05 pmRNSNotification of Major Interest in Shares
25th Mar 20157:00 amRNSPreliminary Results
18th Mar 20157:00 amRNSPain Relief Portfolio Study Commences
16th Mar 20155:48 pmRNSAIM Disclosure
3rd Mar 20154:52 pmRNSNotification of Major Interest in Shares
5th Feb 20157:00 amRNSUS Patent Extension for MED2002
2nd Feb 20151:18 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
28th Jan 20151:10 pmRNSNotification of Major Interest in Shares
23rd Jan 201510:14 amRNSNotification of Major Interest in Shares
22nd Jan 20152:33 pmRNSDirector Shareholding
15th Jan 201512:32 pmRNSNotification of Major Interest in Shares
15th Jan 201512:14 pmRNSDirector's Dealings
15th Jan 20157:00 amRNSNotice of Preliminary Results
5th Jan 20157:00 amRNSRemuneration of Non-Executive Directors
15th Dec 20147:00 amRNSAppointment of CRO for MED2002 Clinical Study
1st Dec 20147:00 amRNSUpdate on Pain Relief Clinical Programme
13th Nov 201410:02 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.